Apoptosis in Chronic Myeloid Leukemia Cells Transiently Treated with Imatinib or Dasatinib Is Caused by Residual BCR-ABL Kinase Inhibition

Investor logo

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Informatics. Official publication website can be found on muni.cz.
Authors

ŠIMARA Pavel STEJSKAL Stanislav KRONTORÁD KOUTNÁ Irena POTĚŠIL David TESAŘOVÁ Lenka POTĚŠILOVÁ Michaela ZDRÁHAL Zbyněk MAYER Jiří

Year of publication 2012
Type Conference abstract
MU Faculty or unit

Faculty of Informatics

Citation
Description Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hemopoietic stem cells. The constitutively active tyrosine kinase BCR-ABL causes defects in the proliferation and differentiation of blood cells. CML is currently treated with tyrosine kinase specific inhibitors (TKIs), such as imatinib, nilotinib, and dasatinib. Transient, potent BCR-ABL inhibition with TKIs was demonstrated to commit CML cells to apoptosis irreversibly (Shah et al., 2008; Snead et al., 2009; Hiwase et al. 2009). This mechanism would explain the clinical efficacy of once-daily dasatinib treatment, despite the rapid clearance of the drug from the plasma. The restoration of BCR-ABL activity after TKI washout was demonstrated using phosphorylated CRKL (p-CRKL) protein as a surrogate marker. Our in vitro data challenges this model. We suggest that apoptosis observed in the BCR-ABL-positive cell lines K562, KYO-1, LAMA-84 and progenitor cells from chronic phase CML patients with transient imatinib and dasatinib treatment is instead caused by residual kinase inhibition that persists as a consequence of intracellular drug retention.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.